Exchange: NASDAQ·Updated 04:10 PM EST

SHPH News

News
all
press releases
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 25.1% to $3.79 during Monday's after-market session. The company's market cap stands at $1.8 million. China Pharma Holding (AMEX:CPHI)read more...
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 25.1% to $3.79 during Monday's after-market session. The company's market cap stands at $1.8 million. China Pharma Holding (AMEX:CPHI)read more...
Benzinga
More News
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) sharesread more...
Benzinga
Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock movedread more...
Benzinga
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose 7.46% toread more...
Benzinga
AI infrastructure plan, SpaceX exposure, and Nasdaq compliance update boosted investor sentiment.
Stocktwits
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursday's after-market session. The company's market cap stands at $2.1 million. INVO Fertility (NASDAQ:IVF) stockread more...
Benzinga
Bitcoin’s price rose to an intraday high of nearly $80,000 as oil prices eased after reports of a potential Iran-U.S. peace deal.
Stocktwits
Shuttle Pharmaceutical Holdings signed a definitive merger agreement to acquire United Dogecoin and become a Dogecoin miner.
Stocktwits
Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.
Stocktwits Contributor
George Scorsis takes helm as Chairman as Ropidoxuridine trial nears 50% enrollment and patent advances boost pipeline.
Stocktwits Contributor

Advertisement|Remove ads.